RBC Capital keeps ARM at Outperform but cuts target to $300 from $340
RBC Capital kept its Outperform rating on ARM Holdings and lowered its price target to $300 from $340, according to TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
RBC Capital kept its Outperform rating on ARM Holdings but cut its price target to $300 from $340, a reduction of 11.8%. According to TradingView, the new target implies a 56.4% gain from the November 4 close of $191.80.
The same TradingView report lists recent notes from other brokers. Barclays maintained an Overweight rating with a $325 target, Wells Fargo kept Overweight with a $255 target, and Piper Sandler reiterated Overweight with a $270 target. Over the past 30 days, the three most recent price targets ranged from $255 to $325.
why it matters
A lower target with an unchanged rating suggests RBC has revised its valuation of the stock without changing its overall stance. Investors tracking analyst sentiment on ARM and the chip sector may find these notes useful, but on their own they are not a trading signal.
tags
instruments
sources
- RBC Capital maintains ARM Holdings at Outperform, lowers price target to $300 from $340 — TradingView, 5 November 2026 at 18:19 UTC
- RBC Capital maintains Datadog at Outperform, lowers price target to $270 from $320 — TradingView, 5 November 2026 at 18:53 UTC
- RBC Capital maintains Design Therapeutics at Outperform, lowers price target to $19 from $20 — TradingView, 5 November 2026 at 18:55 UTC
- RBC Capital maintains HubSpot at Outperform, lowers price target to $260 from $300 — TradingView, 5 November 2026 at 19:27 UTC
- RBC Capital maintains NICE at Outperform, lowers price target to $130 from $145 — TradingView, 5 November 2026 at 19:37 UTC
- RBC Capital maintains Nuvation Bio at Outperform, lowers price target to $17 from $20 — TradingView, 5 November 2026 at 19:43 UTC
- RBC Capital maintains Sprott at Outperform, lowers price target to $189 from $207 — TradingView, 5 November 2026 at 20:02 UTC
- RBC Capital maintains Versigent at Outperform, lowers price target to $52 from $53 — TradingView, 5 November 2026 at 20:06 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗